Davidson Investment Advisors Sells 986 Shares of Celgene Co. (NASDAQ:CELG)

Davidson Investment Advisors reduced its position in shares of Celgene Co. (NASDAQ:CELG) by 0.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 135,498 shares of the biopharmaceutical company’s stock after selling 986 shares during the quarter. Celgene comprises 1.4% of Davidson Investment Advisors’ holdings, making the stock its 26th biggest position. Davidson Investment Advisors’ holdings in Celgene were worth $13,455,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Lindbrook Capital LLC grew its position in shares of Celgene by 14.2% in the 3rd quarter. Lindbrook Capital LLC now owns 829 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 103 shares during the period. Hendley & Co. Inc. lifted its stake in Celgene by 0.3% in the 3rd quarter. Hendley & Co. Inc. now owns 38,282 shares of the biopharmaceutical company’s stock valued at $3,801,000 after acquiring an additional 105 shares in the last quarter. Berman Capital Advisors LLC lifted its stake in Celgene by 11.3% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,096 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 111 shares in the last quarter. Bbva USA Bancshares Inc. lifted its stake in Celgene by 0.8% in the 2nd quarter. Bbva USA Bancshares Inc. now owns 13,271 shares of the biopharmaceutical company’s stock valued at $1,227,000 after acquiring an additional 111 shares in the last quarter. Finally, Plancorp LLC lifted its stake in Celgene by 5.1% in the 2nd quarter. Plancorp LLC now owns 2,336 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 113 shares in the last quarter. Institutional investors own 72.06% of the company’s stock.

In other news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.39% of the company’s stock.

Shares of Celgene stock traded up $0.46 on Tuesday, reaching $110.03. 35,125 shares of the company were exchanged, compared to its average volume of 4,190,941. Celgene Co. has a one year low of $58.59 and a one year high of $109.75. The company has a market capitalization of $77.96 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.52 and a beta of 1.41. The company has a current ratio of 2.89, a quick ratio of 2.80 and a debt-to-equity ratio of 1.51. The company has a 50-day moving average of $102.94 and a 200 day moving average of $96.92.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The company had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.39 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The business’s revenue was up 16.1% compared to the same quarter last year. Analysts predict that Celgene Co. will post 10.7 earnings per share for the current year.

Several research firms have commented on CELG. Leerink Swann set a $115.00 target price on Celgene and gave the company a “hold” rating in a research note on Friday, November 1st. ValuEngine cut Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Cowen restated a “hold” rating and issued a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 target price on the stock. in a research note on Friday, November 1st. Finally, Wells Fargo & Co set a $110.00 target price on Celgene and gave the company a “hold” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $97.31.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What is the price-sales ratio?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit